Book contents
- CASE STUDIES Stahl’s Essential Psychopharmacology
- Reviews
- CASE STUDIES: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- List of icons
- Abbreviations
- Case 1: The salutatorian who couldn’t speak: selective serotonin reuptake inhibitor (SSRI)-refractory anxiety in an adolescent
- Case 2: From anxious to activated: selective serotonin reuptake inhibitor (SSRI)-related activation
- Case 3: The girl who couldn’t sleep: posttraumatic stress disorder (PTSD) in a young girl
- Case 4: Depressed and still depressed: major depressive disorder (MDD) in an adolescent
- Case 5: A 13-year-old adolescent who feels “amazing”: selective serotonin reuptake inhibitor (SSRI)-induced mania in an adolescent
- Case 6: Counting on a cure: obsessive compulsive disorder (OCD) in an adolescent
- Case 7: Struggles in the second grade: attention-deficit hyperactivity disorder (ADHD) in a child
- Case 8: From prodrome to psychosis: early-onset schizophrenia
- Case 9: Too much, too little, or just right? Lithium dosing in an adolescent
- Case 10: Tic, tic, tic: motor and vocal tics in a boy
- Case 11: How slow can you go? Selective serotonin reuptake inhibitor (SSRI) withdrawal and discontinuation in an adolescent
- Case 12: The adolescent who doesn’t eat: anorexia nervosa in an adolescent
- Case 13: High or higher antidepressant concentrations? Cannabis-related drug interactions in an adolescent
- Case 14: The boy whose bed was always wet: nocturnal enuresis in a child
- Case 15: Counting sheep and counting treatment trials: insomnia disorder in an adolescent
- Case 16: Second-generation antipsychotics/mixed dopamine–serotonin receptor agonists (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with autism spectrum disorder (ASD)
- Case 17: The “standard treatment” is earning a “D”: treatment-resistant schizophrenia
- Case 18: Symptoms, side effects, or both? Selective serotonin reuptake inhibitor (SSRI) tolerability and physical symptoms in an anxious adolescent
- Book part
- Case Studies Index
- Drugs Index
- References
Case 2: From anxious to activated: selective serotonin reuptake inhibitor (SSRI)-related activation
Published online by Cambridge University Press: 09 February 2024
Book contents
- CASE STUDIES Stahl’s Essential Psychopharmacology
- Reviews
- CASE STUDIES: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- List of icons
- Abbreviations
- Case 1: The salutatorian who couldn’t speak: selective serotonin reuptake inhibitor (SSRI)-refractory anxiety in an adolescent
- Case 2: From anxious to activated: selective serotonin reuptake inhibitor (SSRI)-related activation
- Case 3: The girl who couldn’t sleep: posttraumatic stress disorder (PTSD) in a young girl
- Case 4: Depressed and still depressed: major depressive disorder (MDD) in an adolescent
- Case 5: A 13-year-old adolescent who feels “amazing”: selective serotonin reuptake inhibitor (SSRI)-induced mania in an adolescent
- Case 6: Counting on a cure: obsessive compulsive disorder (OCD) in an adolescent
- Case 7: Struggles in the second grade: attention-deficit hyperactivity disorder (ADHD) in a child
- Case 8: From prodrome to psychosis: early-onset schizophrenia
- Case 9: Too much, too little, or just right? Lithium dosing in an adolescent
- Case 10: Tic, tic, tic: motor and vocal tics in a boy
- Case 11: How slow can you go? Selective serotonin reuptake inhibitor (SSRI) withdrawal and discontinuation in an adolescent
- Case 12: The adolescent who doesn’t eat: anorexia nervosa in an adolescent
- Case 13: High or higher antidepressant concentrations? Cannabis-related drug interactions in an adolescent
- Case 14: The boy whose bed was always wet: nocturnal enuresis in a child
- Case 15: Counting sheep and counting treatment trials: insomnia disorder in an adolescent
- Case 16: Second-generation antipsychotics/mixed dopamine–serotonin receptor agonists (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with autism spectrum disorder (ASD)
- Case 17: The “standard treatment” is earning a “D”: treatment-resistant schizophrenia
- Case 18: Symptoms, side effects, or both? Selective serotonin reuptake inhibitor (SSRI) tolerability and physical symptoms in an anxious adolescent
- Book part
- Case Studies Index
- Drugs Index
- References
Summary
Which of the following represents an evidence-based intervention for a child with SSRI-related activation?
- Type
- Chapter
- Information
- Case Studies: Stahl's Essential PsychopharmacologyChildren and Adolescents, pp. 17 - 34Publisher: Cambridge University PressPrint publication year: 2023
References
Aldrich, S. L., Poweleit, E. A., Prows, C. A., et al. Influence of CYP2C19 metabolizer status on escitalopram/citalopram tolerability and response in youth with anxiety and depressive disorders. Front Pharmacol 2019; 10: 99. https://doi.org/10.3389/fphar.2019.00099Google Scholar
Barnes, N. M., Sharp, T. A review of central 5-HT receptors and their function. Neuropharmacology 1999; 38: 1083–152. https://doi.org/10.1016/s0028-3908(99)00010-6Google Scholar
Dobson, E. T., Bloch, M. H., Strawn, J. R. Efficacy and tolerability of pharmacotherapy in pediatric anxiety disorders: a network meta-analysis. J Clin Psychiatry 2019; 80: 17r12064. https://doi.org/10.4088/JCP.17r12064Google Scholar
Goldstein, J. A. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52: 349–55. https://doi.org/10.1046/j.0306-5251.2001.01499.xGoogle Scholar
Guile, J. M. Sertraline-induced behavioral activation during the treatment of an adolescent with major depression. J Child Adolesc Psychopharmacol 1996; 6: 281–85. https://doi.org/10.1089/cap.1996.6.281Google Scholar
Hicks, J. K., Bishop, J. R., Sangkuhl, K., et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther 2015; 98: 127–34. https://doi.org/10.1002/cpt.147Google Scholar
King, R. A., Riddle, M. A., Chappell, P. B., et al. Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry 1991; 30: 179–86. https://doi.org/10.1097/00004583-199103000-00003Google Scholar
Kruesi, M. J., Rapoport, J. L., Hamburger, S., et al. Cerebrospinal fluid monoamine metabolites, aggression, and impulsivity in disruptive behavior disorders of children and adolescents. Arch Gen Psychiatry 1990; 47: 419–26. https://doi.org/10.1001/archpsyc.1990.01810170019003Google Scholar
Locher, C., Koechlin, H., Zion, S. R., et al. Efficacy and safety of selective serotonin reuptake inhibitors, serotonin–norepinephrine reuptake inhibitors, and placebo in common psychiatric disorders among children and adolescents: a systematic review and meta-analysis. JAMA Psychiatry 2017; 74: 1011–20. https://doi.org/10.1001/jamapsychiatry.2017.2432Google Scholar
Luft, M. J., Lamy, M., DelBello, M. P., McNamara, R. K., Strawn, J. R. Antidepressant-induced activation in children and adolescents: risk, recognition and management. Curr Probl Pediatr Adolesc Health Care 2018; 48: 50–62. https://doi.org/10.1016/j.cppeds.2017.12.001CrossRefGoogle Scholar
Mills, J. A., Strawn, J. R. Antidepressant tolerability in pediatric anxiety and obsessive-compulsive disorders: a Bayesian hierarchical modeling meta-analysis. J Am Acad Child Adolesc Psychiatry 2020; 59: 1240–51. https://doi.org/10.1016/j.jaac.2019.10.013Google Scholar
Newman-Tancredi, A., Kleven, M. S. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berl) 2011; 216: 451–73. https://doi.org/10.1007/s00213-011-2247-yGoogle Scholar
Placidi, G. P. A., Oquendo, M. A., Malone, K. M., et al. Aggressivity, suicide attempts, and depression: relationship to cerebrospinal fluid monoamine metabolite levels. Biol Psychiatry 2001; 50: 783–91. https://doi.org/10.1016/s0006-3223(01)01170-2Google Scholar
Poweleit, E. A., Mizuno, T., Taylor, Z. L., et al. A Population Pharmacokinetic Analysis of Escitalopram and the Effect of CYP2C19 on Clearance in Children and Adolescents. Annual Meeting of the American Society for Clinical Pharmacology & Therapeutics, Atlanta GA, March 22–24, 2023. Alexandria, VA: American Society for Clinical Pharmacology & Therapeutics, 2023.Google Scholar
Ramsey, L. B., Brown, J. T., Vear, S. I., Bishop, J. R., Van Driest, S. L. Gene-based dose optimization in children. Annu Rev Pharmacol Toxicol 2020; 60: 311–31. https://doi.org/10.1146/annurev-pharmtox-010919-023459Google Scholar
Reinblatt, S. P., DosReis, S., Walkup, J. T., Riddle, M. A. Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents. J Child Adolesc Psychopharmacol 2009; 19: 119–26. https://doi.org/10.1089/cap.2008.040Google Scholar
Riddle, M. A., King, R. A., Hardin, M. T., et al. Behavioral side effects of fluoxetine in children and adolescents. J Child Adolesc Psychopharmacol 1990; 1: 193–8. https://doi.org/10.1089/cap.1990.1.193Google Scholar
Scott, S. A., Sangkuhl, K., Stein, C. M., et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 2013; 94: 317–23. https://doi.org/10.1038/clpt.2013.105Google Scholar
Strawn, J. R., Welge, J. A., Wehry, A. M., Keeshin, B., Rynn, M. A. Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis. Depress Anxiety 2015; 32: 149–57. https://doi.org/10.1002/da.22329Google Scholar
Strawn, J. R., Compton, S. N., Robertson, B., et al. Extended release guanfacine in pediatric anxiety disorders: a pilot, randomized, placebo-controlled trial. J Child Adolesc Psychopharmacol 2017; 27: 29–37. https://doi.org/10.1089/cap.2016.0132Google Scholar
Strawn, J. R., Mills, J. A., Sauley, B. A., Welge, J. A. The impact of antidepressant dose and class on treatment response in pediatric anxiety disorders: a meta-analysis. J Am Acad Child Adolesc Psychiatry 2018; 57: 235–44.e2. https://doi.org/10.1016/j.jaac.2018.01.015Google Scholar
Strawn, J. R., Poweleit, E. A., Ramsey, L. B. CYP2C19-guided escitalopram and sertraline dosing in pediatric patients: a pharmacokinetic modeling study. J Child Adolesc Psychopharmacol 2019; 29: 340–47. https://doi.org/10.1089/cap.2018.0160Google Scholar
Strawn, J. R., Mills, J. A., Schroeder, H., et al. Escitalopram in adolescents with generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychiatry 2020; 81: 20m13396. https://doi.org/10.4088/JCP.20m13396Google Scholar
Strawn, J. R., Lu, L., Peris, T. S., Levine, A., Walkup, J. T. Research review: pediatric anxiety disorders – what have we learnt in the last 10 years? J Child Psychol Psychiatry 2021; 62: 114–39. https://doi.org/10.1111/jcpp.13262CrossRefGoogle ScholarPubMed
Wilens, T. E., Biederman, J., Kwon, A., et al. A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors. J Child Adolesc Psychopharmacol 2003; 13: 143–52. https://doi.org/10.1089/104454603322163862CrossRefGoogle ScholarPubMed